Výsledky vyhledávání - "Koji, Shinozaki"

Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone–Inhibitory Effect of Octreotide after Growth Hormone–Releasing Hormone Stimulation

Autor: Akiteru Seki, Ryusuke Nagasawa, Ken-ichi Ogawara, Junsaku Kitagawa, Tomoya Ohno, Mark Bruce, Koji Shinozaki, Tomoyuki Shono, Takuya Nishio, Tatsuya Komagata, Hirotaka Tanaka, Hiroyuki Iida

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 379:400-408

Acromegaly is a chronic systemic disease characterized by facial and peripheral changes caused by soft tissue overgrowth, together with multiple complications. Despite available surgical and medical therapies, suitable treatments for acromegaly are s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f9845dafc8268dacae0bdbc1b47b17
https://doi.org/10.1124/jpet.121.000769

Zobrazit plný text záznamu

PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline

Autor: Federica Begalli, Joaquin Botta, David Collier, Neil Dorward, Joan Grieve, Danyal Khan, Angelos Kolias, Tatsuya Komagata, Mãrta Korbonits, Kesson Magid, Hani J Marcus, Peter J McCormick, Nigel Mendoza, Ramesh Nair, Thomas Rice, Koji Shinozaki, Oniz Suleyman

Publikováno v: Journal of the Endocrine Society. 6:A548-A549

Clinically non-functioning pituitary adenomas (NFPAs) represent the second most common subtype of pituitary tumours, representing 15-43% of all pituitary adenomas. NFPAs are usually benign tumours with no clinical evidence of hormonal hypersecretion.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd91c8dfb057ea5c5e7afafd832b0283
https://doi.org/10.1210/jendso/bvac150.1140

Zobrazit plný text záznamu

Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease

Autor: Tsubasa Okano, Tomohiro Morio, Masatoshi Takagi, Koji Shinozaki, Noriko Mitsuiki, Kazunaga Agematsu, Mari Tanaka-Kubota, Masakatsu Yanagimachi, Masafumi Yamada, Masahiro Ueki, Hirokazu Kanegane, Satoshi Miyamoto, Kohsuke Imai

Publikováno v: International Journal of Hematology. 107:610-614

Pulmonary alveolar proteinosis (PAP) is a rare disorder that is characterized by the excessive accumulation of surfactant-like materials in the alveoli, leading to hypoxemic respiratory failure. We describe two Japanese infants with PAP associated wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069695e152e47cdd99de8d7447986d4b
https://doi.org/10.1007/s12185-017-2375-1

Zobrazit plný text záznamu

Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia

Autor: Yoshikazu Takaoka, Masahiro Ikura, Hiromu Egashira, Masahiko Terakado, Masaki Asada, Naoko Karakawa, Naoki Matsunaga, Shinji Nakade, Yuka Takada, Keisuke Hirai, Koji Shinozaki, Hiroshi Saga, Kazuya Hashimura, Masanori Yamada, Hideyuki Ueda, Yoshihiro Sugiura, Masashi Minami, Hidehiro Suzuki, Motoyuki Tanaka

Publikováno v: ACS Medicinal Chemistry Letters. 8:1281-1286

Scaffold hopping from the amide group of lead compound ONO-7300243 (1) to a secondary alcohol successfully gave a novel chemotype lysophosphatidic acid receptor 1 (LPA1) antagonist 4. Wash-out experiments using rat isolated urethra showed that compou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67fbce79430dabdbc96ac714da5cb0c5
https://doi.org/10.1021/acsmedchemlett.7b00383

Zobrazit plný text záznamu

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey

Autor: Koji Shinozaki, Tatsuya Komagata, Hiroki Okada, Takuya Nishio, Seishi Katsumata, Akiharu Ishida, Hirotaka Tanaka

Publikováno v: Journal of the Endocrine Society

Purpose: The verification of efficacy of new drug candidates in primate models may address the translational gap between non-clinical and clinical studies and support the prediction of efficacy in humans. Given this, and to support the evaluation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce32a6f0abb6e740dea9de497ab1e44
https://doi.org/10.1210/js.2019-mon-477

Zobrazit plný text záznamu

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells

Autor: Dave S.B. Hoon, Shlomo Melmed, Koji Shinozaki, Adam N. Mamelak, Garni Barkhoudarian, Vivien Bonert, Tatsuya Komagata, Daniel Kelly, Cuiqi Zhou

Publikováno v: Journal of the Endocrine Society

Somatostatin receptor ligands (SRL) and GHR antagonists are used for persistent or recurrent acromegaly following noncurative surgery and as primary therapy for patients unsuitable for surgery. We tested in vitro action of a novel oral SRL compound O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962e390d0b5f2c442f88de4f19293417
https://doi.org/10.1210/js.2019-mon-459

Zobrazit plný text záznamu

MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans

Autor: Hiroyuki Iida, Hirotaka Tanaka, Tatsuya Komagata, Shinichi Neki, Akiharu Ishida, Hiroki Okada, Takeshi Sawada, Seishi Katsumata, Koji Shinozaki

Publikováno v: Journal of the Endocrine Society

Somatostatin analogues (SSAs) are indicated for use in acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP NETs). However, SSAs are administered as injections which can be a challenge for patients and healthcare providers. ONO-5788 is a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc821fd8c0b0826e6533cef54651d8f3
https://doi.org/10.1210/js.2019-mon-464

Zobrazit plný text záznamu

Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives

Autor: Kazuhiro Otsuki, Hiroshi Yamamoto, Haruto Kurata, Ai Hashimoto, Koji Shinozaki, Takeshi Matsushita, Takuya Seko, Yoshiyuki Yamaura, Tetsuya Sekiguchi, Kensuke Kusumi, Akito Kakuuchi, Atsushi Naganawa

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 26:1209-1213

The structure of the S1P2 antagonist 1 has been modified with the aim of improving its oral bioavailability. The chemical modification of the alkyl chain and carboxylic acid moieties of 1 led to significant improvements in the oral exposure of compou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d25a2df178b653cedb5d031676d280d5
https://doi.org/10.1016/j.bmcl.2016.01.031

Zobrazit plný text záznamu

Surgical methods and clinical results of subfascial endoscopic perforator surgery in Japan

Autor: Kenji Matsuzaki, Ryoji Takeda, Ryo Shinhara, Naoki Haruta, Hitoshi Kusagawa, Koji Shinozaki, Atsushi Tabuchi, Kunie Kohno, Hiromitsu Sugawara, Yuji Hoshino, Hiroyuki Niihara, Hidetoshi Nagata

Publikováno v: Phlebology. 33(10)

ObjectivesTo clarify the surgical methods and the clinical results of subfascial endoscopic perforator surgery in Japan.MethodsThis study included 1287 limbs of 1091 patients who underwent subfascial endoscopic perforator surgery in 14 hospitals. Sim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aeb1b448f22e0aa002764610b7eaf3e
https://pubmed.ncbi.nlm.nih.gov/29301462

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání